Combinations strategies involving checkpoint immunotherapies were approved as first-line options in two cancer types and showed promise in clinical trials for several hard-to-treat cancers. Important advances were also made with respect to immune-related biomarkers, cellular immunotherapies, and personalized vaccines. Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, is focusing her research(...)
Elizabeth Jaffee
Cancer Matters with Dr. Bill Nelson – New AACR President Dr. Elizabeth Jaffee
Posted by | podcastDr Bill Nelson, the Director of the Kimmel Cancer Center at Johns Hopkins, begins a new podcast series focused on cancer treatment and research. In episode one, Dr Nelson speaks with Dr Elizabeth Jaffee, the Kimmel Cancer Center’s Deputy Director and the Associate Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, from the annual meeting(...)